NewsRoom Articles - Page 25 of 251

WednesdayFeb 15, 2023 9:00 am

Prime Harvest Inc. Prepares to Expand Retail Footprint with Approval Recommendation From San Diego Planning Group

San Diego Planning Group grants approval recommendation to Prime Harvest Inc. to open retail cannabis outlet in Mount Hope Community planning groups often appeal retail cannabis applications, resulting in long delays, court cases, and project abandonment Prime Harvest received local support by meeting with community stakeholders, revealed plans to integrate community’s needs into project Prime Harvest is a member of the Community Alliance Program, provides financial assistance for educational programs, homeless veterans, urban farms, and the arts Opening a cannabis retail outlet in San Diego is not an easy process, but Prime Harvest, a legal tech-focused cannabis enterprise and parent…

FridayFeb 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28 patents granted and roughly 50 patent applications pending worldwide For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human…

WednesdayFeb 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending Speaking during a late…

MondayFeb 06, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year

2022 saw Lexaria introduce its patented DehydraTECH(TM) technology to world-leading collaborators while also exploring DehydraTECH-CBD for the potential treatment of hypertension It also saw success in its research for the potential treatment of conditions such as epilepsy, making the year Lexaria’s most active one yet Significant progress was made on key objectives in 2022, a feat which the company plans to capitalize on and leverage to scale up the commercial execution of its technology in 2023 To facilitate this, Lexaria has brought on board Julian Gangolli, former President of GW Pharmaceuticals USA, as a strategic advisor. Chris Bunka, Lexaria’s CEO,…

FridayJan 27, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023

Lexaria Bioscience recently released its 2023 annual letter from CEO Chris Bunka, providing a strategic update to all stakeholders The letter highlights the key milestones achieved in calendar 2022, outlines expectations for calendar 2023, and indicates why Chris Bunka expects 2023 to be the company’s best year so far 1In calendar 2023, Lexaria expects to attain FDA registration for an investigational new drug (“IND”) program and commence Phase 1(b) clinical study evaluating the safety and tolerability of DehydraTECH(TM)-processed CBD as a treatment for hypertension The company will also be pursuing commercial relationships in 2023 even as its R&D continues to…

WednesdayJan 25, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream…

WednesdayJan 11, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancers This patent inches Lexaria closer to taking advantage of the cosmeceuticals market, projected…

MondayJan 09, 2023 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients

Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure The company also reported that it had demonstrated superior CBD blood absorption levels in its HYPER-H21-4 study from DehydraTECH-CBD relative to those of published comparators At the lowest (3.38 mg/kg) and highest (4.46 mg/kg) dose levels tested, DehydraTECH-CBD resulted in…

FridayJan 06, 2023 11:15 am

Flora Growth Corp. (NASDAQ: FLGC) Acquisition of Franchise Global Health Completed, Rapid Jump in Potential for European Cannabis Sales

International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies regard as the doorway to the rest of Europe, and it also has a footprint in Portugal and Denmark, while Flora Growth has completed exports to Switzerland and the Czech Republic Flora reported a 604…

WednesdayJan 04, 2023 11:15 am

Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands

The 36-person human pharmacokinetic randomized, double-blind, cross-over study NIC-H22-1 will compare its patented DehydraTECH(TM)-nicotine to leading nicotine pouches On! and Zyn The white pouch oral delivery of nicotine is thought to avoid harmful lung outcomes that smokers and vapers experience The global nicotine pouch market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, driven by an increase in the number of consumers seeking alternative forms of nicotine that do not involve lung exposure Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced that dosing has commenced for its human…

News and publishing service for hemp related companies

Contact us: 512.354.7000

Prime Harvest Inc. Prepares to Expand Retail Footprint with Approval Recommendation From San Diego Planning Group

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients

Flora Growth Corp. (NASDAQ: FLGC) Acquisition of Franchise Global Health Completed, Rapid Jump in Potential for European Cannabis Sales

Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands

HempWire Currently Accepts

HempWire

News and publishing service for hemp related companies

Contact us: 512.354.7000

HempWire Currently Accepts

Company Search

Site Search